H3b-6527 asco
WebEvidence suggests that hyperactivated fibroblast growth factor 4 (FGFR4) signaling pathway leads to enhanced tumor growth. Targeting FGFR4 may have therapeutic benefit in tumors with altered FGF19 signaling. A phase I study (NCT02834780) was undertaken to assess H3B-6527, a highly selective covalent FGFR4 inhibitor, in patients with HCC/ICC. WebAug 28, 2024 · H3B-6527, an investigational FGFR inhibitor, has demonstrated early signs of activity in patients with hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC), according to findings presented in a poster at the 2024 ASCO Annual Meeting. The first-in-human phase I study also showed the agent is well tolerated.
H3b-6527 asco
Did you know?
WebJul 16, 2024 · The FGFR4 inhibitor H3B-6527 was effective against FGFR4 N535K but not against FGFR4 V550L (a known gate keeper mutation) (Supplementary Fig. 7). The multikinase inhibitor dovitinib demonstrated ... WebH3B-6527 plasma levels increased with dose from 300 to 1000 mg QD and plateaued. H3B-6527 was rapidly absorbed with a t max of ~2-3 h and showed a terminal half-life of ~4-5 h, following administration of 1000 mg (fasted). No dose-limiting toxicities or ≥ Grade 3 treatment-related AEs (TRAE) have been observed in escalation.
WebMay 26, 2024 · H3B-6527 plasma levels increased with dose from 300 to 1000 mg QD and plateaued. H3B-6527 was rapidly absorbed with a t max of ~2-3 h and showed a … WebOther FGFR4 inhibitors in development and under evaluation are BLU9931/BLU554 [38,39] and H3B-6527 [40][41] [42]. In a first-in-human study with BLU-554 in patients with HCC, the ORR was 17% in ...
WebDec 14, 2024 · H3B-6527 did not hit any other line in the 625 cell line panel demonstrating both the selectivity of H3B-6527 and the selective dependence on FGFR4 across cancer types. Palbociclib enhances H3B-6527 antitumor activity. The data described so far indicate that H3B-6527 as a single agent is efficacious in FGF19-overexpressing HCC models. WebH3B-6527 is a highly selective covalent FGFR4 inhibitor with an IC50 value of <1.2 nM and at least 250-fold selectivity over FGFR1-3 (IC50 values of 320, 1,290 and 1,060 nM …
WebMay 28, 2024 · H3B-6527 Cmax and AUC were lower at 300 mg dose but then similar across 500–2000 mg doses. Following oral administration of 1000 mg fasted, H3B-6527 …
WebMay 16, 2024 · The clinical data abstracts published online today for the H3B-6545 and H3B-6527 Phase 1 studies reflect data as of December 18, 2024 and January 6, 2024, respectively. Updated results from both studies will be presented at ASCO. The schedule for H3’s ASCO presentations is as follows: H3B-6545 Presentations. Abstract Number: 1059 skyward springs valley high schoolWebMay 16, 2024 · The latest information on H3B-6527 (fibroblast growth factor receptor 4 inhibitor) and H3B-6545 (selective estrogen receptor covalent antagonist), which were discovered by Eisai's U.S. oncology precision medicine-focused research and development subsidiary H3 Biomedicine Inc., will also be highlighted in presentations at ASCO. swedish hospital nurse lineWebA Phase I study of H3B-6527 in hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC) patients (pts). (ASCO 2024) - P1; "H3B-6527 is well tolerated and demonstrates early signs of clinical activity. Dose expansion on QD schedule and exploration of BID (twice daily) schedule is ongoing. swedish hospital issaquah washingtonWebPRODUCTS AT ASCO ANNUAL MEETING Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the latest data ... Phase I study of H3B-6527 in hepatocellular carcinoma (HCC) or ... Phase 1b study of H3B-6545 in combination with palbociclib in women with metastatic estrogen receptor-positive (ER+), human epidermal ... skyward specialty insurance glassdoorWebJul 18, 2024 · At the 2024 ASCO Annual Meeting, Gutierrez presented data for the first-in-human phase I trial of H3B-6527 in patients with advanced HCC or ICC. Gutierrez says … swedish hospital partnersWebMay 20, 2024 · H3 Biomedicine Announces Presentation of Four Abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting Article Stock Quotes (2) FREE Breaking News Alerts from ... skyward specialty insurance loginWebMay 29, 2024 · Many of the studies being presented at ASCO report on novel treatments for patients with recurrent or persistent lymphoma or multiple myeloma, including innovative precision medicine approaches. ... A phase I study of H3B-6527 in hepatocellular carcinoma or intrahepatic cholangiocarcinoma (ICC) patients (abstract 4095) skyward specialty insurance surety